Michał Borys
Lublin, 20-081, Poland
NCT Number: NCT03143738
Comparison of continuous adductor canal block to continuous femoral nerve block in patients after total knee arthroplasty.
All patients will be anesthetized with spinal anesthesia. Continuous infusion of ropivacaine with a catheter implemented to the adductor canal or next to the femoral nerve.
The observed goals: pain intensity, the beginning and quality of rehabilitation.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Lublin, 20-081, Poland
Written consent will be obtained a day before the surgery. Only subarachnoidally anaesthetised patients may participate in the study. Pencil-point spinal needle and bupivacaine (Marcaine Heavy Spinal 0.5 %) will be used.
Before the beginning of operation, under ultrasound control, a catheter will be implemented to one of the chosen position: the adductor canal (the middle or lower third of thigh) or near the femoral nerve (below the inguinal ligament). The local anesthetic solution of 0.2 % ropivacaine will be started with an elastomeric pump (5 mL per hour, up to 72 hours) as soon as a catheter in the right position.
The pain will be measured with VAS (visual-analogue scale) 8, 24 and 48 hours after the end of operation, and at the discharge. At the same time, i.e.: 8, 24 and 48 hours from the end of surgery, the range of flexion and extension in the operated knee will be assessed. Moreover, the possibility of patient's sitting, standing up and walking will be noted.
All parameters will be reassessed before patients' discharge from the hospital. Each patient will receive paracetamol (1.0) and metamizol (1.0) intravenously (i.v.) q6h. 5 mg of morphine may be given as required, up to 2 dosages per day as a rescue medication.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented to the adductor canal and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented next to the femoral nerve (below inguinal ligament) and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
Before the beginning of surgery all patients will be anesthetised with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 2.0 - 2.5 mL solution. Pencil point spinal needle will be used.
Other names: Subarachnoid anesthesia
Time frame: 24 hours from the end of surgery
Total consumption of intravenous morphine by patients with the use of patient-controlled analgesia pump
Time frame: 8, 24, 48 hours from the end of surgery, and at the patient discharge from the hospital (an average 4-6 days)
range of flexion in operated knee
Time frame: 8, 24, 48 hours from the end of surgery, and at the patient discharge from the hospital (an average 4-6 days)
Possibility of walking by patients at scheduled time points
Time frame: 8, 24, 48 hours from the end of surgery, and at the patient discharge from the hospital (an average 4-6 days)
Measured with VAS (visual-analogue scale)
Time frame: 8, 24, 48 hours from the end of surgery, and at the patient discharge from the hospital (an average 4-6 days)
Possibility of walking by patients at scheduled time points
Medical University of Lublin
Other
Continuous Adductor Canal Block in Comparison to Continuous Femoral Nerve Block in Patients After Total Knee Arthroplasty: Randomized Control Trail
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05575700
Acute Pain, Agnosia
Brøndby, Denmark
View Trial DetailsNCT05834023
Acute Pain, Agnosia
San Carlos, Región de Ñuble, Chile
View Trial DetailsNCT04123873
Acute Pain, Agnosia
Næstved, Danmark, Denmark
View Trial DetailsNCT07249827
Acute Pain, Agnosia
Montreal, Quebec, Canada
View Trial Details